Freeline gives detailed look at hemophilia gene therapy results
Bio Pharma Dive
JULY 21, 2022
The London-based drugmaker is currently seeking a partner to continue development of the hemophilia B treatment, which has shown promise in testing but trails a rival therapy from CSL Behring and UniQure.
Let's personalize your content